The association between CD157/BST1 polymorphisms and the susceptibility of Parkinson’s disease: a meta-analysis

Abstract

Background: Different studies have provided some evidence for the association between BST1 polymorphisms and Parkinson’s disease (PD). The extent to which these genetic effects are consistent across different populations is unknown.

Methods: A meta-analysis of PD case-control studies using a common set of three variants was conducted. Published reports were obtained from electronic databases including Pubmed, Embase, Chinese National Knowledge Infrastructure (CNKI) and Cochrane Library databases between August 2010 and January 2018.

Results: A total of 11 individual studies with 8,725 cases and 17,079 controls were included. The results showed statistically significant association between the dominant model of rs11931532 and PD risk in Asian populations (P=0.006, OR [95% CI]=1.22 [1.06–1.41]). Significant association was also detected between the allelic, dominant, and recessive models of rs4698412 and PD risk in Asian populations (allelic model: P<0.00001, OR [95% CI]=1.22 [1.16–1.29]; dominant model: P<0.00001, OR [95%CI]=1.35 [1.20–1.52]; recessive model; P=0.0003, OR [95% CI]=1.30 [1.13–1.50]). Nevertheless, the pooled analyses suggested that no significant association was uncovered between rs11724635 and PD risk (P>0.05).

Conclusion: The meta-analysis suggests that the rs11931532 and rs4698412, but not rs11724635 might be risk factors for PD in Asian populations.

Keywords:

• BST1
• Parkinson’s disease
• polymorphisms
• risk factor

Acknowledgments

The authors thank Professor Yan Zhang for revising the whole manuscript. This study was funded by the National Natural Science Foundation of China (Grant No. 81873780), the Foundation of the Health Department of Hunan (No. B2017041), the Foundation of the Education Department of Hunan (16A027, 13C1115, 13C1116, and 16C0167), The foundation of Hunan national science (The Youngth Item) (No. 2019JJ50697), The Application Characteristic Discipline of Hunan Province, The Hunan Key Laboratory Cultivation Base of the Research and Development of Novel Pharmaceutical Preparations (No. 2016TP1029), and The Hunan Provincial Innovation Platform and Talents Program (No. 2018RS3105).

Disclosure

The authors report no conflicts of interest in this work.

Supplementary material

Table S1 Methodological quality of the included studies according to the Newcastle-Ottawa scale